Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum

(2013) I. Raz et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

(2013) S. Madsbad   DIABETES OBESITY & METABOLISM

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

(2013) B. Charbonnel et al.   DIABETOLOGIA

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

(2010) C. J. Girman et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

(2010) et al.   Journal of Diabetes Investigation

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2010

(2009)   DIABETES CARE

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET